Combined bezafibrate, medroxyprogesterone acetate and valproic acid treatment inhibits osteosarcoma cell growth without adversely affecting normal mesenchymal stem cells. by Sheard, Jonathan J. et al.
Title: Combined bezafibrate, medroxyprogesterone acetate and valproic acid treatment 
inhibits osteosarcoma cell growth without adversely affecting normal mesenchymal stem 
cells. 
 
Running heading: Repurposed drugs that selectively target human osteosarcoma 
 
Authors: Jonathan J. Sheard
1
, Andrew D. Southam
2
, Hannah L. MacKay
3
, Max A. 
Ellington
4
, Martyn D. Snow
5
, Farhat L. Khanim
6
, Christopher M. Bunce
6







Life and Health Sciences, Aston University, Birmingham B4 7ET, UK (current address, 
Sheard BioTech Ltd., Sheraton House, Chorleywood, Rickmansworth, WD3 5LH, UK); 
2
School of Biosciences, University of Birmingham, Birmingham B15 2TT, UK;  
3
Institute of Cancer and Genomic Studies, University of Birmingham, Birmingham B15 2TT, 
UK; 
4
University Centre Shrewsbury, Guildhall, Frankwell Quay, Shrewsbury SY3 8HQ, UK;  
5
Royal Orthopaedic Hospital, Birmingham B31 2AP, UK; 
 
6
School of Biomedical Sciences, University of Birmingham, Birmingham B15 2TT, UK; 
7
Chester Medical School, Faculty of Medicine and Life Sciences, University of Chester, 
Chester CH1 4BJ, UK. 
 
*Corresponding author: Professor W. Eustace Johnson, Chester Medical School, Faculty of 
Medicine, Dentistry and Life Sciences, University of Chester, Parkgate Road, Chester CH1 




Drug repurposing is a cost effective means of targeting new therapies for cancer. We have 
examined the effects of the repurposed drugs, bezafibrate, medroxyprogesterone acetate and 
valproic acid on human osteosarcoma cells, i.e., SAOS2 and MG63 compared with their 
normal cell counterparts, i.e. mesenchymal stem/stromal cells (MSCs). Cell growth, viability 
and migration were measured by biochemical assay and live cell imaging, whilst levels of 
lipid-synthesising enzymes were measured by immunoblotting cell extracts. These drug 
treatments inhibited the growth and survival of SAOS2 and MG63 cells most effectively 
when used in combination (termed V-BAP). In contrast, V-BAP treated MSCs remained 
viable with only moderately reduced cell proliferation. V-BAP treatment also inhibited 
migratory cell phenotypes. MG63 and SAOS2 cells expressed much greater levels of fatty 
acid synthase and stearoyl CoA desaturase 1 than MSCs, but these elevated enzyme levels 
significantly decreased in the V-BAP treated osteosarcoma cells prior to cell death. Hence, 
we have identified a repurposed drug combination that selectively inhibits the growth and 
survival of human osteosarcoma cells in association with altered lipid metabolism without 
adversely affecting their non-transformed cell counterparts.  
Key words 
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Introduction 
Combinatorial drug treatments are more effective in the treatment of many different types of 
tumour than monotherapies as this increases the number of aberrant signalling or pathogenic 
pathways that can be targeted. In osteosarcoma, which, although rare, is the most common 
form of bone tumour affecting children and adolescents 
1
, the current chemotherapeutic drug 
regimen includes a combination of methotrexate, cisplatin, doxorubicin and ifosfamide 
2
. 
However, these drugs demonstrate toxicity against normal cells and have limited effect on 
metastatic osteosarcoma, for which patients have a relatively poor prognosis 
2,3
. Therefore, 
new drug combinations are required that selectively target osteosarcoma and do not adversely 
affect normal cell counterparts. This search for new anti-tumour therapies has included a 
strategic repurposing of drugs that are already licensed for clinical application and of proven 
safety 
4
. For example, the histone deacetylase inhibitor, valproic acid (VPA), which is used 
clinically to treat epilepsy 
5
, augments the effects of cytotoxic anti-tumour drugs against 
osteosarcomas by enhancing expression of apoptosis-related genes 
6
. 
In blood cancers, i.e. leukaemia and lymphoma, combination therapies and drug 
repurposing, as well as problems of drug toxicity, are also seen as strategically important and 
novel drug regimens have successfully increased patient survival rates for some forms of 
haemopoietic malignancy. For example, we recently combined the lipid-regulating drug 
bezafibrate (BEZ) and the sex hormone medroxyprogesterone acetate (MPA) (combined 
treatments were termed BaP) to induce cell growth arrest, apoptosis and increased 
differentiation of acute myeloid leukaemia (AML) in vitro 
7
. In addition, we showed 
therapeutic efficacy in a clinical trial of low dose BaP therapy in elderly and relapsed AML 
8
. 
BaP therapy also prevented disease progression in a phase I/II trial in endemic Burkett’s 
lymphoma 
9
. There were no evident adverse effects on normal haemopoietic stem cells or 
progenitors at the low drug concentrations used in this study. The mechanisms of action of 
these drugs are complex and likely to be disease-specific, although data suggest that 
generation of reactive oxygen species (ROS) and altered prostaglandin and fatty acid 
synthesis is important 
8,10
. Disruption of stearoyl CoA desaturase 1 (SCD-1)-mediated 
lipogenesis, in particular, was associated with the cytotoxic effects of BaP against AML 
10
.  
Aberrant signalling and metabolic pathways that BaP target are implicated in the 
formation of tumours thought to derive from the transformation of mesenchymal 
stromal/stem cells (MSCs), including osteosarcoma 
11
 and chondrosarcoma 
12
. Hence, there is 
an intriguing possibility that the biochemical, molecular and cytotoxic effects of drugs that 
have been successfully re-profiled to treat haemopoietic malignancies may also prove 
efficacious in other forms of cancer, i.e. MSC-derived sarcomas. Therefore, this study has 
examined the effects of BEZ, MPA and VPA, alone and in combination, on the growth, 
survival and migratory behaviour of human osteosarcoma cells in comparison with normal 
(non-transformed) human MSCs.  
 
Results 
The comparative effects of repurposed drugs on human osteosarcoma versus normal 
MSC growth, viability and migration 
Combined treatments with BEZ, MPA and VPA (termed V-BAP) were more effective in 
inhibiting the growth and survival of SAOS2 and MG63 osteosarcoma cells than single 
treatments of each drug alone (Figure 1). The effects on V-BAP on the numbers of viable 
osteosarcoma cells (assessed by MTT assay) were significant and drug concentration-
dependent. Hence, at V-BAP concentrations of 1mM BEZ, 10μM MPA and 0.6mM VPA, the 
number of viable SAOS2 and MG63 cells present in treated cultures was less than 2% of 
control numbers. In contrast, V-BAP treatment had little effect on the growth and survival of 
human MSCs, such that at a V-BAP concentration of 1mM BEZ, 10μM MPA and 0.6mM 
VPA, the viable MSC number was still approximately 95% of control values, with no 
significant difference. At greater concentrations of V-BAP, i.e. at 2mM BEZ, 20μM MPA 
and 0.6mM VPA, the number of viable human MSCs decreased to less than 50% of control 
values. Hence, there was an effective concentration range of V-BAP that blocked the growth 
of SAOS2 and MG63 cells, but had no adverse effect on human MSCs. Furthermore, in 
separate studies we found that V-BAP treatment was significantly more effective at inhibiting 
SAOS2 and MG63 cell proliferation than the drug combination of BaP alone (Supplementary 
Figure S2).  
The combined drug treatments of 0.5mM BEZ, 5μM MPA and 0.6mM VPA (designated V-
BAP Low) versus 1mM BEZ, 10μM MPA and 0.6mM VPA (designated V-BAP High) 
marked a transition from drug concentrations that prevented the growth of SAOS2 cells only 
to a concentration that effectively prevented the growth of SAOS2 and MG63 cells, with the 
growth of human MSCs remaining unaffected. Therefore, these two concentrations were 
examined further.  
We used time-lapse live cell image analysis combined with DRAQ7™ staining to examine 
whether V-BAP treated cells were undergoing growth arrest and/or were also dying. SAOS2 
and MG63 cells showed greater proliferation than their non-transformed MSC counterparts, 
as measured by the number of cell divisions recorded over a 120 hour culture period. 
However, there was a significant reduction in the number of viable SAOS2 and MG63 cells 
undergoing cell division (versus control cultures) after drug treatments, which was associated 
with an increase in cells staining positively for DRAQ7 (Figure 2). In contrast, there was no 
significant change in the numbers of viable MSCs undergoing cell division when treated with 
either V-BAP Low or V-BAP High concentrations. This data confirmed that V-BAP 
treatment was not simply affecting cell metabolic rates, which the MTT assay would also 
detect, but was inhibiting osteosarcoma cell proliferation and survival. 
In the absence of drug treatment, MG63 cells and human MSCs had a migratory phenotype, 
with increased trajectory lengths and migratory speeds when compared with SAOS2 cells 
(Figure 3A). However, cell migration was inhibited for all cell types following treatment with 
V-BAP. For MG63 cells only, the inhibitory effect of V-BAP treatment on trajectory length 
was significant (Figure 3B).  
 
The lipogenic enzymes fatty acid synthase (FASN) and stearoyl CoA desaturase (SCD-1) 
are elevated in human osteosarcoma cells compared with MSC and down-regulated 
after V-BAP treatment 
Immunoblotting of cell extracts demonstrated that FASN and SCD-1 levels were very low or 
non-detectable in human MSCs compared with the osteosarcoma cell lines (Figure 4). 
However, following 48 hours of V-BAP High treatment there was a significant decrease in 
FASN and SCD-1 in SAOS2 and MG63 cell lines (Figure 5). At this time point post-
treatment, the V-BAP treated and control SAOS2 and MG63 culture viabilities were not 
significantly different and greater than 95% cells were viable in all cases.  
 
Discussion 
A combinatorial drug regime of BEZ and MPA (BaP) was recently demonstrated to target 
AML and endemic Burkitt’s lymphoma with little effect on the survival of normal adult 
haemopoietic progenitor cells 
7,9
. In addition, the histone deacetylase (HDAC) inhibitor, 
VPA, was reported to reduce the growth-inhibitory and cytotoxic effects of doxorubicin in 
osteosarcoma cell lines 
16
.  Therefore, we hypothesised that a similar drug regime of BEZ and 
MPA combined with VPA may selectively target osteosarcoma cells, whilst preserving their 
non-transformed cell counterparts, i.e. human MSCs. Following individual drug treatments 
for 5 days (120 hours), BEZ and VPA treatments alone significantly reduced SAOS2 and 
MG63 cell viability to a greater extent than treatments with MPA alone, in a concentration-
dependent manner. We then combined BEZ and MPA treatments in doubling dilutions that 
mimicked those previously reported as effective against haemopoietic cells 
7,8,17-19
, with the 
addition of a single concentration of VPA (0.6mM) that is clinically safe and effective as an 
anti-convulsant 
5
. Combinatorial treatments with BEZ, MPA and VPA (V-BAP) inhibited the 
growth of SAOS2 and MG63 cells to a greater extent than single treatments with each drug 
alone, in a BaP concentration-dependent manner, whilst still having much less effect on the 
growth of human MSCs. For the V-BAP drug combination, the concentrations of VPA and 
MPA that were effective in inhibiting SAOS2 and MG63 cell proliferation, i.e., 0.6 mM VPA 
and up to 10μM MPA, respectively, are very likely to be achievable in humans, although the 
detailed pharmacokinetics for combination therapies have not been performed. In paediatric 
Burkitt’s lymphoma, treatment of patients with BEZ at levels that are likely equivalent to 
those concentrations of <0.5mM BEZ that were used in this in vitro study, i.e., at 400mg per 
day, also were well tolerated 
9
. However, higher doses of BEZ can be problematic, 
particularly in older patients with poor kidney function, as was seen more recently in a BaP 
dose escalation study 
20
. Therefore, the development of V-BAP as a potential therapeutic for 
patients with osteosarcoma would require careful examination of drug tolerance and dose 
escalation and monitoring of creatinine kinase levels and estimated glomerular filtration rate. 
Live cell imaging and lineage tracking experiments demonstrated that in control conditions, 
human MSCs were relatively slow to proliferate, but remained viable throughout the culture 
period and exhibitory a migratory phenotype. As expected, SAOS2 and MG63 osteosarcoma 
cells in control conditions proliferated more rapidly, also remaining viable throughout the 
culture period. MG63 cells exhibited a similar migratory phenotype to human MSCs, whilst 
the SAOS2 cells were the least migratory – with both a relatively short trajectory distance 
and slow migratory speed. Following treatment with V-BAP, both the numbers of viable 
SAOS2 and MG63 cells dividing during the culture period and the migration of these cells 
were reduced. For both of the osteosarcoma cell lines, the inhibitory effects of V-BAP on 
viable cell division were concentration-dependent and significantly different to any effects on 
human MSCs, for which there was no significant effect. Cell migration was reduced for all 
cell types, but only significantly so for MG63 cells. Hence, this study has demonstrated proof 
of concept that combined BEZ, MPA and VPA treatment has deleterious effects on the 
growth and migration of human osteosarcoma cells without adversely affecting non-
transformed human MSCs. 
The mechanisms of action of V-BAP in targeting osteosarcoma cells are likely to be complex 
and warrant subsequent studies. VPA has been used in clinical practice as an anticonvulsant 
for more than four decades 
21
 and at higher doses is known to function as a HDAC inhibitor 5, 
which can result in general hyperacetylation of histones and increased transcriptional activity 
through relaxation of DNA conformation 
22
. Khanim et al., (2009) reported that BAP 
treatment of AML cells increased pools of prostaglandin D2 (PGD2) via: (i) MPA-mediated 
inhibition of the PGD2 metabolising enzyme Aldo-Keto Reductase (AKR) 1C3, and (ii) 
increased PGD2 synthesis through the isoprostane pathway, which was resultant from BEZ-
induced reactive oxygen species (ROS) generation and lipid peroxidation 
7
. In the absence of 
AKRIC3 activity (blocked by MPA) PGD2 spontaneously generates 15-deoxy Δ
12, 
14
prostaglandin J2 (15d-PGJ2) 
7
, an endogenous ligand for peroxisome proliferator-activated 
receptor-γ (PPARγ). Increased activation of PPARγ by 15d-PGJ2 and other ligands has been 
associated with growth inhibition and increased apoptotic cell death in a wide variety of 
malignancies 
23
. For example, ROS-induced 15d-PGJ2 synthesis in SAOS2, MG63 and U2 
OS osteosarcoma cells, resulted in cell cycle inhibition 11. Treatment of chondrosarcoma cells 
with the selective PPARγ  ligand pioglitazone or 15d-PGJ2 also inhibited their proliferation 
and induced apoptosis in a dose-dependent manner 
24
. The action of 15d-PGJ2 was more 
potent than pioglitazone which may reflect additional non-PPARγ-dependent actions of this 
electrophilic prostanoid that also covalently modifies nucleophiles, such as the free cysteine 
residues of proteins 
25
. Another study identified that 15d-PGJ2 induced chondrosarcoma cell 
apoptosis is associated with down-regulation of the anti-apoptotic gene Bcl-xL and up-
regulation of pro-apoptotic gene Bax 
12
. Ewing’s sarcomas, again thought to derive from 
MSC transformation 
26
, are sensitive to TRAIL through binding to death receptor 5 (DR5) 
27
. 
It is therefore important to note that in Jurkat lymphoma and prostate cancer cells, 15d-PGJ2 
elevation was associated with PPARγ independent increases in protein levels of DR5 
mediated by mRNA stabilization, potentiating TRAIL-induced apoptosis 
28
. 
We have shown here that FASN and SCD-1 levels are much greater in SAOS2 and MG63 
cells compared to normal human MSCs and these elevated levels decreased significantly 
following V-BAP treatment. FASN is a putative diagnostic indicator for osteosarcoma and its 
inhibition induces cell growth arrest, apoptosis and reduced cell migration in U2-OS 
osteosarcoma cells 
29
. In addition, increased levels of SCD-1 are associated with a poor 
prognosis for patients with soft tissue sarcomas 
30
. Hence, changes in ROS, PPARγ-
dependent and PPARγ-independent activities of 15d-PGJ2, and altered monosaturated 
lipogenesis each represent plausible combinatorial mechanisms for the selective action of V-
BAP against osteosarcoma cells when compared to non-transformed MSCs.   
In summary, this study has demonstrated that a novel drug combination, V-BAP, 
significantly inhibited the growth and viability of human osteosarcoma cells compared with 
non-transformed human MSCs. This supports the concept that drug combination and re-
deployment strategies that have shown promise in the targeted treatment of one form of 




Cell culture: Human MSCs were obtained from excised human knee fat-pad tissue following 
donor informed consent and ethical approval (12/EE/0136; National Research Ethics Service 
(NRES) Committee, East of England Hertfordshire). The experiment protocol for the 
research involving humans and donated tissues was in accordance with NRES guidelines 
following ethical approval and the Declaration of Helsinki. The adipose tissue was washed 
and digested with collagenase and MSCs selected according to their preferential adhesion to 
tissue culture plastic before culture expanding in DMEM/F12 culture medium supplemented 
with 10% fetal calf serum (FCS) and 1% penicillin and streptomycin (standard culture 
medium, all Gibco, Fisher Scientific, Loughborough, UK) in a humidified atmosphere at 
37
o
C and 5% CO2. Stock cultures of MSCs, SAOS2 and MG63 osteosarcoma cells were 
maintained by routine passaging at 70% confluence and re-seeding into fresh culture flasks at 




.  We have shown previously 
13
 that these adipose-derived MSCs 
exhibit the necessary characteristics in terms of plastic adherence, CD immunoprofile and 




Drug treatments: BEZ, MPA and VPA (all Sigma-Aldrich Ltd., Dorset, UK) were stored at -
20
o
C as stock concentrations of 10
-2
M (in dexamethasone, ethanol or cell culture dH2O, 
respectively). After thawing, these were diluted to final concentrations as indicated in the 
results section in standard culture medium. Identical dilutions of solvent carrier(s) alone were 
used in control cultures. Human MSCs, SAOS2 or MG63 cells were seeded in standard 
culture medium in 48 or 96 well plates at a density of 5x10
3
 cells/well and left to adhere 
overnight. After this time, the culture medium was replaced with drug-supplemented or 
control culture medium and cells cultured for a further 120 hours in a humidified atmosphere 
at 37
o
C and 5% CO2.  
Cell viability assays: Staining with tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT; Sigma-Aldrich Ltd) and DRAQ7™ (Bio Status Ltd, 
Leicestershire, UK) was used to measure metabolically active (viable) cell numbers, adapting 
methods previously reported 
15
. For the MTT assay, the enzymatic formation of formazan 
was measured by spectrophotometry at 492nm, corrected for background values at 650nm, 
and these values have been presented normalised to the mean control values. Viability was 
further assessed by DRAQ7™ (Abcam Ltd., Cambridge, UK), a fluorescent dye that stains 
permeabilised dead/dying cells without adversely affecting viable cells. DRAQ7™ 
incorporation was quantitated using the Cell-IQ system during live-cell imaging and lineage 
tracking, as described below.  
Live cell image capture and analysis: Live-cell imaging and analysis were conducted using 
the Cell-IQ Imagen live-cell imaging platform and Cell-IQ Analyser image analysis software 
(Cell-IQ version 2, CM Technologies Oy, Tampere, Finland), which performs continuous 
live-cell imaging of cells maintained within an incubator under intermittent phase contrast 
and fluorescence microscopy. Upon selection of desired regions of interest (ROI), the system 
was used to collect digitised images over time. For lineage tracking, the Cell-IQ Analyser 
Manual Cell Lineage-Tracking tool was used to track individual cells of each cell type 
throughout the culture period, i.e. for each experiment using human MSCs, SAOS2 and 
MG63 cells, where the mean numbers of cells examined in each experiment were 35 ± 11, 92 
± 17 and 62 ± 18 (mean ± standard error of the mean), respectively. The proliferation and 
migration of cells was assessed using the same collected digitised images and software, 
where we measured: (i) the number of viable cell divisions; (ii) the trajectory distance; (iii) 
the migratory speed of viable cells for human MSCs, SAOS2 and MG63 cells throughout the 
culture period.  
Western blotting: Immunoblotting for the lipogenic enzymes, FASN and SCD-1, was 
performed as described previously 
10
. In brief, V-BAP treated and control sub-confluent 
(80%) cultures of SAOS2, MG63 cells and human MSCs were harvested after 48 hours by 
trypsinisation and pelleted by centrifugation. Following suspension in phosphate buffered 
saline (PBS) and re-pelleting, cell extracts were prepared by lysis using 
radioimmunoprecipitation assay (RIPA) buffer. Thirty micrograms of protein for each cell 
sample was combined with Laemmli 4x loading dye (Bio-Rad, Fisher Scientific Ltd.) and 
10% beta-mercaptoethanol (Sigma-Aldrich Ltd.) and heated for 5 minutes at 70
o
C. Cell 
extracts were separated using SDS-PAGE precast gradient gels (4%-15%; Bio-Rad), proteins 
transferred to Immobilon-P membrane (Millicorp, Sigma-Aldrich Ltd.). Membranes were 
sectioned in two parts at ~60KDa, the lower half probed with 1/1,000 dilutions of anti-SCD-1 
(ab19862; Abcam Ltd.), and the upper half with anti-ACC1 (4190; New England Biolabs 
Ltd.), anti-phospho-ACC Ser79 (11818; New England Biolabs Ltd.), and anti-FASN 
(ab22759; Abcam Ltd). The lower half of the membrane was probed with anti-β-actin 
antibodies (SigmaAldrich Ltd) diluted at 1/25,000 as loading control. Densitometry was 
performed using ImageJ software (http://rsb.info.nih.gov/ij/) and protein expression 
normalized to β-actin. 
Statistical analysis: At least 3 independent experiments were performed for all data shown, 
i.e., testing the effects of single treatment and drug combinations on human MSC cultures 
from at least 3 different donors and testing the SAOS2 and MG63 cell lines on at least 3 
independent occasions. Data was tested for normal distribution and 2-way ANOVAs used to 
examine the significance of drug treatments on viable cell number, cell division and cell 
migration with post-hoc Tukey tests or t tests applied to examine differences between 
individual groups and concentrations. Data has been shown as means±standard error of the 
mean (SEM); p values of <0.05 were considered significant. 
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Figure legends 
Figure 1. Combined treatments with V-BAP selectively inhibited SAOS2 and MG63 
osteosarcoma cell proliferation. 
MTT assays of viable cell numbers were performed after 120 hours of culture in the presence 
of increasing concentrations of (A) BEZ, (B) MPA and (C) VPA as single drug treatments. 
Cells are designated as follows: SAOS2: orange, MG63: red, human MSCs: green. . (D) Drug 
combinations of VPA (0.6mM) with increasing concentrations BEZ and MPA (termed, V-
BAP). Data shown as mean±SEM (n=3 independent experiments) **p˂0.01, ***p˂0.001. 
Significant differences between both osteosarcoma cell lines and human MSCs have been 
indicated only. 
 
Figure 2. V-BAP treatment induced cell death and significantly inhibited SAOS2 and 
MG63 cell division with minimal effect on human MSCs. 
(A) Representative digitised images of human MSCs, SAOS2 and MG63 cells within control 
conditions at 0 hours (top panels) and at 120 hours culture in control (upper middle panels) 
versus V-BAP High [1mM BEZ, 10μM MPA, 0.6mM VPA] treated conditions (lower middle 
panels). Non-viable DRAQ7
TM
 stained cells appear blue. (B) Representative lineage trees of 
human MSCs (green), SAOS2 (orange) and MG63 cells (red) tracked over 120hrs of culture 
in control conditions (top panels) versus V-BAP Low [0.5mM BEZ, 5μM MPA, 0.6mM 
VPA] (middle panels) and V-BAP High [1mM BEZ, 10μM MPA, 0.6mM VPA] (bottom 
panels) treatment conditions. Lineage termination prior to the end of 120 hours indicates cell 
death (determined by DRAQ7
TM
 staining). (C) The numbers of viable cell divisions in control 
versus V-BAP Low and V-BAP High treatments over 120 hours. Data shown as means±SEM 
(n=3 independent experiments), *p˂0.05, **p˂0.01, ***p˂0.001. 
  
Figure 3. V-BAP treatment inhibited cell migration.  
(A) Representative centred trajectory plots illustrate the trajectory paths of multiple human 
MSCs, SAOS2 and MG63 cells over 120hrs of treatment in control (top panels) and V-BAP 
High [1mM BEZ, 10μM MPA, 0.6mM VPA] (bottom panels) treatment conditions. (B) The 
trajectory lengths (left graph) and migratory speeds (right graph) of human MSCs (green), 
SAOS2 (orange) and MG63 (red) cells in control versus V-BAP Low [0.5mM BEZ, 5μM 
MPA, 0.6mM VPA] and V-BAP High [1mM BEZ, 10μM MPA, 0.6mM VPA] treated 
cultures. Data shown as means±SEM (n=3 independent experiments), *p˂0.05, **p˂0.01. 
 
Figure 4. SAOS2 and MG63 osteosarcoma cells express greater levels of FASN and 
SCD-1 compared to human MSCs.  
(A). Representative immunoblots of cell extracts for FASN and SCD-1 from human MSCs 
(n=3 donors shown), SAOS2 and MG63 cells. (B) Scanning densitometry of FASN and 
SCD-1 protein levels. Data shown as means ± SEM (n=3 experiments), *p˂0.05, **p˂0.01. 
 
Figure 5. V-BAP treatment down-regulated FASN and SCD-1 levels in SAOS2 and 
MG63 osteosarcoma cells.  
Cell lysates were prepared for SAOS2 (A) and MG63 (B) cells treated for 48 hours with 
either control versus V-BAP High [1mM BEZ, 10μM MPA, 0.6mM VPA]. Proteins were 
separated on gradient SDS-PAGE. After transfer, membranes were cut in half and the upper 
half probed for FASN. The lower half of the membrane was probed for SCD1 and -actin as 
loading control Representative western blots are shown together with bar charts of 
means±SEM of n>3 experiments. Significance is denoted by *p˂0.05, **p˂0.01. 
 
Supplementary Figure 1. All SDS-PAGE and Western blotting performed to determine 
FASN and SCD-1 levels in cell lines.  
The original images from all experiments performed to generate data shown in Figure 4 and 
Figure 5 have been shown as un-cropped images, with individual single or paired (control 
versus VBAP treatment) lanes that were used in main Figures highlighted. Note that for all 
blots, the membranes were cut at 100kD with the upper section probed with antibodies for 
FASN or SCD-1 and the lower section (0-100kD) probed with antibodies for actin.  
 
Supplementary Figure 2. V-BAP treatment more effectively inhibited SAOS2 and 
MG63 osteosarcoma cell proliferation than BaP treatment.   
MTT assays of viable cell numbers were performed after 120 hours of culture in the presence 
of increasing concentrations of BEZ and MPA in V-BAP compared with BaP alone. Data 
shown as mean±SEM (a minimum of n=3 independent experiments) **p˂0.01, ***p˂0.001. 
Post-hoc analysis for significant differences between V-BAP versus BaP at each 
concentration have been indicated. 
 
 
 







